2I9 Stock Overview
A venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Karolinska Development AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.069 |
| 52 Week High | SEK 0.17 |
| 52 Week Low | SEK 0.061 |
| Beta | 0.19 |
| 11 Month Change | -17.37% |
| 3 Month Change | -34.51% |
| 1 Year Change | -51.00% |
| 33 Year Change | -87.90% |
| 5 Year Change | -80.37% |
| Change since IPO | -91.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2I9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.9% | -1.2% | -0.02% |
| 1Y | -51.0% | -20.1% | 8.2% |
Return vs Industry: 2I9 underperformed the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: 2I9 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 2I9 volatility | |
|---|---|
| 2I9 Average Weekly Movement | 22.1% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2I9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2I9's weekly volatility has increased from 15% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 8 | Viktor Drvota | www.karolinskadevelopment.com |
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark.
Karolinska Development AB (publ) Fundamentals Summary
| 2I9 fundamental statistics | |
|---|---|
| Market cap | €24.45m |
| Earnings (TTM) | -€2.48m |
| Revenue (TTM) | €163.31k |
149.7x
P/S Ratio-9.9x
P/E RatioIs 2I9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2I9 income statement (TTM) | |
|---|---|
| Revenue | SEK 1.88m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 1.88m |
| Other Expenses | SEK 30.41m |
| Earnings | -SEK 28.53m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,519.01% |
| Debt/Equity Ratio | 0% |
How did 2I9 perform over the long term?
See historical performance and comparison